Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 253 to 263 of 263 entries
Sorted by: Best Match Show Resources per page
Differential cross sections for pi +p and pi -p elastic scattering from 378 to 687 MeV/c.

Physical review. D, Particles and fields

Briscoe WJ, Fitzgerald DH, Nefkens BM, Sadler ME, Seftor CJ.
PMID: 9957981
Phys Rev D Part Fields. 1987 May 01;35(9):2718-2735. doi: 10.1103/physrevd.35.2718.

No abstract available.

Cite
Briscoe WJ, Fitzgerald DH, Nefkens BM, et al. Differential cross sections for pi +p and pi -p elastic scattering from 378 to 687 MeV/c. Phys Rev D Part Fields. 1987;35(9):2718-2735doi: 10.1103/physrevd.35.2718.
Briscoe, W. J., Fitzgerald, D. H., Nefkens, B. M., Sadler, M. E., & Seftor, C. J. (1987). Differential cross sections for pi +p and pi -p elastic scattering from 378 to 687 MeV/c. Physical review. D, Particles and fields, 35(9), 2718-2735. https://doi.org/10.1103/physrevd.35.2718
Briscoe, et al. "Differential cross sections for pi +p and pi -p elastic scattering from 378 to 687 MeV/c." Physical review. D, Particles and fields vol. 35,9 (1987): 2718-2735. doi: https://doi.org/10.1103/physrevd.35.2718
Briscoe WJ, Fitzgerald DH, Nefkens BM, Sadler ME, Seftor CJ. Differential cross sections for pi +p and pi -p elastic scattering from 378 to 687 MeV/c. Phys Rev D Part Fields. 1987 May 01;35(9):2718-2735. doi: 10.1103/physrevd.35.2718. PMID: 9957981.
Copy Download .nbib Format: NLM
Superratio and the simple ratios of pi + and pi - elastic scattering on 3H and 3He at 180 MeV to investigate charge symmetry.

Physical review. C, Nuclear physics

Briscoe WJ, Eichon AD, Fitzgerald DH, Mokhtari A, Nefkens BM, Sadler ME, Wightman JA.
PMID: 9966660
Phys Rev C Nucl Phys. 1990 Jun;41(6):2770-2782. doi: 10.1103/physrevc.41.2770.

No abstract available.

Cite
Briscoe WJ, Eichon AD, Fitzgerald DH, et al. Superratio and the simple ratios of pi + and pi - elastic scattering on 3H and 3He at 180 MeV to investigate charge symmetry. Phys Rev C Nucl Phys. 1990;41(6):2770-2782doi: 10.1103/physrevc.41.2770.
Briscoe, W. J., Eichon, A. D., Fitzgerald, D. H., Mokhtari, A., Nefkens, B. M., Sadler, M. E., & Wightman, J. A. (1990). Superratio and the simple ratios of pi + and pi - elastic scattering on 3H and 3He at 180 MeV to investigate charge symmetry. Physical review. C, Nuclear physics, 41(6), 2770-2782. https://doi.org/10.1103/physrevc.41.2770
Briscoe, et al. "Superratio and the simple ratios of pi + and pi - elastic scattering on 3H and 3He at 180 MeV to investigate charge symmetry." Physical review. C, Nuclear physics vol. 41,6 (1990): 2770-2782. doi: https://doi.org/10.1103/physrevc.41.2770
Briscoe WJ, Eichon AD, Fitzgerald DH, Mokhtari A, Nefkens BM, Sadler ME, Wightman JA. Superratio and the simple ratios of pi + and pi - elastic scattering on 3H and 3He at 180 MeV to investigate charge symmetry. Phys Rev C Nucl Phys. 1990 Jun;41(6):2770-2782. doi: 10.1103/physrevc.41.2770. PMID: 9966660.
Copy Download .nbib Format: NLM
Dynamic egg color mimicry.

Ecology and evolution

Hanley D, Šulc M, Brennan PL, Hauber ME, Grim T, Honza M.
PMID: 27516874
Ecol Evol. 2016 May 24;6(12):4192-202. doi: 10.1002/ece3.2187. eCollection 2016 Jun.

Evolutionary hypotheses regarding the function of eggshell phenotypes, from solar protection through mimicry, have implicitly assumed that eggshell appearance remains static throughout the laying and incubation periods. However, recent research demonstrates that egg coloration changes over relatively short, biologically...

Cite
Hanley D, Šulc M, Brennan PL, et al. Dynamic egg color mimicry. Ecol Evol. 2016;6(12):4192-202doi: 10.1002/ece3.2187.
Hanley, D., Šulc, M., Brennan, P. L., Hauber, M. E., Grim, T., & Honza, M. (2016). Dynamic egg color mimicry. Ecology and evolution, 6(12), 4192-202. https://doi.org/10.1002/ece3.2187
Hanley, Daniel, et al. "Dynamic egg color mimicry." Ecology and evolution vol. 6,12 (2016): 4192-202. doi: https://doi.org/10.1002/ece3.2187
Hanley D, Šulc M, Brennan PL, Hauber ME, Grim T, Honza M. Dynamic egg color mimicry. Ecol Evol. 2016 May 24;6(12):4192-202. doi: 10.1002/ece3.2187. eCollection 2016 Jun. PMID: 27516874; PMCID: PMC4972242.
Copy Download .nbib Format: NLM
High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes.

Diabetes care

Jacobsen LM, Haller MJ, Parish A, Gurka MJ, Levine SR, Wasserfall C, Campbell-Thompson M, Kaddis J, Pugliese A, Atkinson MA, Schatz DA.
PMID: 28679687
Diabetes Care. 2017 Sep;40(9):e122-e123. doi: 10.2337/dc17-0996. Epub 2017 Jul 05.

No abstract available.

Cite
Jacobsen LM, Haller MJ, Parish A, et al. High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes. Diabetes Care. 2017;40(9):e122-e123doi: 10.2337/dc17-0996.
Jacobsen, L. M., Haller, M. J., Parish, A., Gurka, M. J., Levine, S. R., Wasserfall, C., Campbell-Thompson, M., Kaddis, J., Pugliese, A., Atkinson, M. A., & Schatz, D. A. (2017). High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes. Diabetes care, 40(9), e122-e123. https://doi.org/10.2337/dc17-0996
Jacobsen, Laura M, et al. "High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes." Diabetes care vol. 40,9 (2017): e122-e123. doi: https://doi.org/10.2337/dc17-0996
Jacobsen LM, Haller MJ, Parish A, Gurka MJ, Levine SR, Wasserfall C, Campbell-Thompson M, Kaddis J, Pugliese A, Atkinson MA, Schatz DA. High Illicit Drug Abuse and Suicide in Organ Donors With Type 1 Diabetes. Diabetes Care. 2017 Sep;40(9):e122-e123. doi: 10.2337/dc17-0996. Epub 2017 Jul 05. PMID: 28679687.
Copy Download .nbib Format: NLM
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.

BMJ open

Wilhelm-Benartzi CS, Miller SE, Bruggraber S, Picton D, Wilson M, Gatley K, Chhabra A, Marcovecchio ML, Hendriks AEJ, Morobé H, Chmura PJ, Bond S, Aschemeier-Fuchs B, Knip M, Tree T, Overbergh L, Pall J, Arnaud O, Haller MJ, Nitsche A, Schulte AM, Mathieu C, Mander A, Dunger D.
PMID: 34876434
BMJ Open. 2021 Dec 07;11(12):e053669. doi: 10.1136/bmjopen-2021-053669.

INTRODUCTION: Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin-producing β cells of the pancreas. One immunosuppressive agent that has recently shown promise in the treatment of new-onset T1D subjects aged 12-45...

Cite
Wilhelm-Benartzi CS, Miller SE, Bruggraber S, et al. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open. 2021;11(12):e053669doi: 10.1136/bmjopen-2021-053669.
Wilhelm-Benartzi, C. S., Miller, S. E., Bruggraber, S., Picton, D., Wilson, M., Gatley, K., Chhabra, A., Marcovecchio, M. L., Hendriks, A. E. J., Morobé, H., Chmura, P. J., Bond, S., Aschemeier-Fuchs, B., Knip, M., Tree, T., Overbergh, L., Pall, J., Arnaud, O., Haller, M. J., Nitsche, A., Schulte, A. M., Mathieu, C., Mander, A., & Dunger, D. (2021). Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ open, 11(12), e053669. https://doi.org/10.1136/bmjopen-2021-053669
Wilhelm-Benartzi, Charlotte S, et al. "Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes." BMJ open vol. 11,12 (2021): e053669. doi: https://doi.org/10.1136/bmjopen-2021-053669
Wilhelm-Benartzi CS, Miller SE, Bruggraber S, Picton D, Wilson M, Gatley K, Chhabra A, Marcovecchio ML, Hendriks AEJ, Morobé H, Chmura PJ, Bond S, Aschemeier-Fuchs B, Knip M, Tree T, Overbergh L, Pall J, Arnaud O, Haller MJ, Nitsche A, Schulte AM, Mathieu C, Mander A, Dunger D. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open. 2021 Dec 07;11(12):e053669. doi: 10.1136/bmjopen-2021-053669. PMID: 34876434; PMCID: PMC8655536.
Copy Download .nbib Format: NLM
Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes.

Diabetes care

Walker AF, Hood KK, Gurka MJ, Filipp SL, Anez-Zabala C, Cuttriss N, Haller MJ, Roque X, Naranjo D, Aulisio G, Addala A, Konopack J, Westen S, Yabut K, Mercado E, Look S, Fitzgerald B, Maizel J, Maahs DM.
PMID: 34001535
Diabetes Care. 2021 Jul;44(7):1480-1490. doi: 10.2337/dc20-2753. Epub 2021 May 17.

OBJECTIVE: Disparities in type 1 diabetes related to use of technologies like continuous glucose monitors (CGMs) and utilization of diabetes care are pronounced based on socioeconomic status (SES), race, and ethnicity. However, systematic reports of perspectives from patients in...

Cite
Walker AF, Hood KK, Gurka MJ, et al. Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Diabetes Care. 2021;44(7):1480-1490doi: 10.2337/dc20-2753.
Walker, A. F., Hood, K. K., Gurka, M. J., Filipp, S. L., Anez-Zabala, C., Cuttriss, N., Haller, M. J., Roque, X., Naranjo, D., Aulisio, G., Addala, A., Konopack, J., Westen, S., Yabut, K., Mercado, E., Look, S., Fitzgerald, B., Maizel, J., & Maahs, D. M. (2021). Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Diabetes care, 44(7), 1480-1490. https://doi.org/10.2337/dc20-2753
Walker, Ashby F, et al. "Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes." Diabetes care vol. 44,7 (2021): 1480-1490. doi: https://doi.org/10.2337/dc20-2753
Walker AF, Hood KK, Gurka MJ, Filipp SL, Anez-Zabala C, Cuttriss N, Haller MJ, Roque X, Naranjo D, Aulisio G, Addala A, Konopack J, Westen S, Yabut K, Mercado E, Look S, Fitzgerald B, Maizel J, Maahs DM. Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Diabetes Care. 2021 Jul;44(7):1480-1490. doi: 10.2337/dc20-2753. Epub 2021 May 17. PMID: 34001535; PMCID: PMC8323174.
Copy Download .nbib Format: NLM
J/psi polarization in 800-GeV p-Cu interactions.

Physical review letters

Chang TH, Beddo ME, Brown CN, Carey TA, Cooper WE, Gagliardi CA, Garvey GT, Geesaman DF, Hawker EA, He XC, Isenhower LD, Kaplan DM, Kaufman SB, Koetke DD, McGaughey PL, Lee WM, Leitch MJ, Moss JM, Mueller BA, Papavassiliou V, Peng JC, Reimer PE, Sadler ME, Sondheim WE, Stankus PW, Towell RS, Tribble RE, Vasiliev MA, Webb JC, Willis JL, Young GR.
PMID: 14683289
Phys Rev Lett. 2003 Nov 21;91(21):211801. doi: 10.1103/PhysRevLett.91.211801. Epub 2003 Nov 21.

We present measurements of the polarization of the J/psi produced in 800-GeV proton interactions with a copper target. Polarization of the J/psi is sensitive to the ccmacr; production and hadronization processes. A longitudinal polarization is observed at large x(F),...

Cite
Chang TH, Beddo ME, Brown CN, et al. J/psi polarization in 800-GeV p-Cu interactions. Phys Rev Lett. 2003;91(21):211801doi: 10.1103/PhysRevLett.91.211801.
Chang, T. H., Beddo, M. E., Brown, C. N., Carey, T. A., Cooper, W. E., Gagliardi, C. A., Garvey, G. T., Geesaman, D. F., Hawker, E. A., He, X. C., Isenhower, L. D., Kaplan, D. M., Kaufman, S. B., Koetke, D. D., McGaughey, P. L., Lee, W. M., Leitch, M. J., Moss, J. M., Mueller, B. A., Papavassiliou, V., Peng, J. C., Reimer, P. E., Sadler, M. E., Sondheim, W. E., Stankus, P. W., Towell, R. S., Tribble, R. E., Vasiliev, M. A., Webb, J. C., Willis, J. L., Young, G. R. (2003). J/psi polarization in 800-GeV p-Cu interactions. Physical review letters, 91(21), 211801. https://doi.org/10.1103/PhysRevLett.91.211801
Chang, T H, et al. "J/psi polarization in 800-GeV p-Cu interactions." Physical review letters vol. 91,21 (2003): 211801. doi: https://doi.org/10.1103/PhysRevLett.91.211801
Chang TH, Beddo ME, Brown CN, Carey TA, Cooper WE, Gagliardi CA, Garvey GT, Geesaman DF, Hawker EA, He XC, Isenhower LD, Kaplan DM, Kaufman SB, Koetke DD, McGaughey PL, Lee WM, Leitch MJ, Moss JM, Mueller BA, Papavassiliou V, Peng JC, Reimer PE, Sadler ME, Sondheim WE, Stankus PW, Towell RS, Tribble RE, Vasiliev MA, Webb JC, Willis JL, Young GR. J/psi polarization in 800-GeV p-Cu interactions. Phys Rev Lett. 2003 Nov 21;91(21):211801. doi: 10.1103/PhysRevLett.91.211801. Epub 2003 Nov 21. PMID: 14683289.
Copy Download .nbib Format: NLM
Multicomponent shell traits are consistent with an individual recognition function of the appearance of common murre (.

Ecology and evolution

Ducay RL, Luro AB, Hansen ES, Hauber ME.
PMID: 33717464
Ecol Evol. 2021 Feb 14;11(5):2402-2409. doi: 10.1002/ece3.7264. eCollection 2021 Mar.

In dense breeding colonies, and despite having no nest structure, common murres (or guillemots:

Cite
Ducay RL, Luro AB, Hansen ES, et al. Multicomponent shell traits are consistent with an individual recognition function of the appearance of common murre (. Ecol Evol. 2021;11(5):2402-2409doi: 10.1002/ece3.7264.
Ducay, R. L., Luro, A. B., Hansen, E. S., & Hauber, M. E. (2021). Multicomponent shell traits are consistent with an individual recognition function of the appearance of common murre (. Ecology and evolution, 11(5), 2402-2409. https://doi.org/10.1002/ece3.7264
Ducay, Rebecca L, et al. "Multicomponent shell traits are consistent with an individual recognition function of the appearance of common murre (." Ecology and evolution vol. 11,5 (2021): 2402-2409. doi: https://doi.org/10.1002/ece3.7264
Ducay RL, Luro AB, Hansen ES, Hauber ME. Multicomponent shell traits are consistent with an individual recognition function of the appearance of common murre (. Ecol Evol. 2021 Feb 14;11(5):2402-2409. doi: 10.1002/ece3.7264. eCollection 2021 Mar. PMID: 33717464; PMCID: PMC7920776.
Copy Download .nbib Format: NLM
Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study.

Pediatric diabetes

Driscoll KA, Tamura R, Johnson SB, Gesualdo P, Clasen J, Smith L, Jacobsen L, Elding Larsson H, Haller MJ.
PMID: 33179853
Pediatr Diabetes. 2021 Mar;22(2):360-368. doi: 10.1111/pedi.13149. Epub 2021 Jan 06.

OBJECTIVE: To examine adherence to the oral glucose tolerance test (OGTT) in multiple islet autoantibody children in stage 1 of developing type 1 diabetes (T1D).METHODS: Children are followed from birth in The Environmental Determinants of Diabetes in the Young...

Cite
Driscoll KA, Tamura R, Johnson SB, et al. Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study. Pediatr Diabetes. 2021;22(2):360-368doi: 10.1111/pedi.13149.
Driscoll, K. A., Tamura, R., Johnson, S. B., Gesualdo, P., Clasen, J., Smith, L., Jacobsen, L., Elding Larsson, H., Haller, M. J. (2021). Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study. Pediatric diabetes, 22(2), 360-368. https://doi.org/10.1111/pedi.13149
Driscoll, Kimberly A, et al. "Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study." Pediatric diabetes vol. 22,2 (2021): 360-368. doi: https://doi.org/10.1111/pedi.13149
Driscoll KA, Tamura R, Johnson SB, Gesualdo P, Clasen J, Smith L, Jacobsen L, Elding Larsson H, Haller MJ. Adherence to oral glucose tolerance testing in children in stage 1 of type 1 diabetes: The TEDDY study. Pediatr Diabetes. 2021 Mar;22(2):360-368. doi: 10.1111/pedi.13149. Epub 2021 Jan 06. PMID: 33179853; PMCID: PMC7913602.
Copy Download .nbib Format: NLM
Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes.

BMJ open

Wilhelm-Benartzi CS, Miller SE, Bruggraber S, Picton D, Wilson M, Gatley K, Chhabra A, Marcovecchio ML, Hendriks AEJ, Morobé H, Chmura PJ, Bond S, Aschemeier-Fuchs B, Knip M, Tree T, Overbergh L, Pall J, Arnaud O, Haller MJ, Nitsche A, Schulte AM, Mathieu C, Mander A, Dunger D.
PMID: 34876434
BMJ Open. 2021 Dec 07;11(12):e053669. doi: 10.1136/bmjopen-2021-053669.

INTRODUCTION: Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin-producing β cells of the pancreas. One immunosuppressive agent that has recently shown promise in the treatment of new-onset T1D subjects aged 12-45...

Cite
Wilhelm-Benartzi CS, Miller SE, Bruggraber S, et al. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open. 2021;11(12):e053669doi: 10.1136/bmjopen-2021-053669.
Wilhelm-Benartzi, C. S., Miller, S. E., Bruggraber, S., Picton, D., Wilson, M., Gatley, K., Chhabra, A., Marcovecchio, M. L., Hendriks, A. E. J., Morobé, H., Chmura, P. J., Bond, S., Aschemeier-Fuchs, B., Knip, M., Tree, T., Overbergh, L., Pall, J., Arnaud, O., Haller, M. J., Nitsche, A., Schulte, A. M., Mathieu, C., Mander, A., & Dunger, D. (2021). Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ open, 11(12), e053669. https://doi.org/10.1136/bmjopen-2021-053669
Wilhelm-Benartzi, Charlotte S, et al. "Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes." BMJ open vol. 11,12 (2021): e053669. doi: https://doi.org/10.1136/bmjopen-2021-053669
Wilhelm-Benartzi CS, Miller SE, Bruggraber S, Picton D, Wilson M, Gatley K, Chhabra A, Marcovecchio ML, Hendriks AEJ, Morobé H, Chmura PJ, Bond S, Aschemeier-Fuchs B, Knip M, Tree T, Overbergh L, Pall J, Arnaud O, Haller MJ, Nitsche A, Schulte AM, Mathieu C, Mander A, Dunger D. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open. 2021 Dec 07;11(12):e053669. doi: 10.1136/bmjopen-2021-053669. PMID: 34876434.
Copy Download .nbib Format: NLM
A recurrent de novo ATP5F1A substitution associated with neonatal complex V deficiency.

European journal of human genetics : EJHG

Lines MA, Cuillerier A, Chakraborty P, Naas T, Duque Lasio ML, Michaud J, Pileggi C, Harper ME, Burelle Y, Toler TL, Sondheimer N, Crawford HP, Millan F, Geraghty MT.
PMID: 34483339
Eur J Hum Genet. 2021 Nov;29(11):1719-1724. doi: 10.1038/s41431-021-00956-0. Epub 2021 Sep 06.

Mitochondrial disorders are a heterogeneous group of rare, degenerative multisystem disorders affecting the cell's core bioenergetic and signalling functions. Spontaneous improvement is rare. We describe a novel neonatal-onset mitochondriopathy in three infants with failure to thrive, hyperlactatemia, hyperammonemia, and...

Cite
Lines MA, Cuillerier A, Chakraborty P, et al. A recurrent de novo ATP5F1A substitution associated with neonatal complex V deficiency. Eur J Hum Genet. 2021;29(11):1719-1724doi: 10.1038/s41431-021-00956-0.
Lines, M. A., Cuillerier, A., Chakraborty, P., Naas, T., Duque Lasio, M. L., Michaud, J., Pileggi, C., Harper, M. E., Burelle, Y., Toler, T. L., Sondheimer, N., Crawford, H. P., Millan, F., & Geraghty, M. T. (2021). A recurrent de novo ATP5F1A substitution associated with neonatal complex V deficiency. European journal of human genetics : EJHG, 29(11), 1719-1724. https://doi.org/10.1038/s41431-021-00956-0
Lines, Matthew A, et al. "A recurrent de novo ATP5F1A substitution associated with neonatal complex V deficiency." European journal of human genetics : EJHG vol. 29,11 (2021): 1719-1724. doi: https://doi.org/10.1038/s41431-021-00956-0
Lines MA, Cuillerier A, Chakraborty P, Naas T, Duque Lasio ML, Michaud J, Pileggi C, Harper ME, Burelle Y, Toler TL, Sondheimer N, Crawford HP, Millan F, Geraghty MT. A recurrent de novo ATP5F1A substitution associated with neonatal complex V deficiency. Eur J Hum Genet. 2021 Nov;29(11):1719-1724. doi: 10.1038/s41431-021-00956-0. Epub 2021 Sep 06. PMID: 34483339; PMCID: PMC8560863.
Copy Download .nbib Format: NLM
Showing 253 to 263 of 263 entries